Clinical study of mebendazole therapy for strongyloidiasis.

概要

論文の詳細を見る
A study was conducted of 225 patients in Okinawa Prefecture, Japan, to evaluate mebendazole (MBZ) therapy for <I>Strongyloides stercoralis</I>. Various schedules were used with the following results : 1) The eradication rates at 12 months after a single course of MBZ therapy (100 mg of a powder twice a day orally for 28 days) and a combination therapy (thiabendazole 500 mg powder form three times daily for 5 days followed by 100 mg of MBZ in powder form twice a day for 9 days, repeated once) were 85.0% (17 of 20 patients) and 100% (17 of 17 patients), respectively. 2) The eradication rates at 3-9 months after using MBZ alone in varying dosages were as follows : (a) 100 mg in powder form twice a day for 5 days, repeated at 1, 3 and 4 weeks following : 80.0% (24/30); (b) 100 mg in powder form twice daily for 5 days repeated at 1 and 3 weeks following : 83.3% (5/6); (c) 100 mg in powder form twice a day for 4 days repeated at 1, 3 and 4 weeks following : 96.0% (24/25); (d) a 100 mg tablet twice a day for 4 days repeated at 1, 3 and 4 weeks following : 90.6% (29/32). 3) The eradication rate at 24 days after a 2-course treatment (a 100 mg tablet twice daily for 4 days repeated 1 week later) was 93.8% (15/16). Although the 2-course treatment was effective, further study seems necessary as the follow-up time was too short and the number of patients was too few.
日本熱帯医学会の論文